To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect.

First page of article

Mortality after the diagnosis of pancreatic ductal adenocarcinoma remains high for all patients. The role of multimodal therapy, including surgical resection and systemic chemotherapy, has been well established. Neoadjuvant treatment strategies continue to be used in resectable and borderline resectable PDAC. Results from ongoing or recently completed trials will continue to provide valuable insight into the management of patients with resectable and borderline resectable PDAC. Advances in the outcomes for this difficult disease and therefore the focus of futures studies should include a better understanding of tumor biology and markers, novel treatment agents, and combination treatment strategies.

To access this article, please choose from the options below

Purchase access to this article

Claim Access

If you are a current subscriber with Society Membership or an Account Number, claim your access now.

Subscribe to this title

Purchase a subscription to gain access to this and all other articles in this journal.

Institutional Access

Visit ScienceDirect to see if you have access via your institution.

 

Linked Articles

Unknown widget #d2170c4d-a9cf-482f-ac17-ef77d57a1866

of type linkedContentList

Related Articles

Unknown widget #c2ffda61-8426-42f7-926b-03d7330eede2

of type relatedArticleListWidget